NeuroVive Pharmaceutical (NVP) - Mitochondrial medicine specialist

09:17 EDT 29 Jun 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - NeuroVive Pharmaceutical: NeuroVive Pharmaceutical is a mitochondrial medicine specialist with a diversified asset portfolio. It employs a two-pronged strategy and has a portfolio of drug candidates for orphan mitochondrial diseases, which it aims to develop internally; more recently, it has also identified in-house assets suitable to tackle larger indications, which NeuroVive aims to out-license in pre-clinical development. The most advanced projects are Phase IIb ready NeuroSTAT for traumatic brain injury and KL1333 in Phase I for various mitochondrial diseases. We value NeuroVive at SEK1.5bn.
ISIN: SE0002575340

Original Article: NeuroVive Pharmaceutical (NVP) - Mitochondrial medicine specialist


More From BioPortfolio on "NeuroVive Pharmaceutical (NVP) - Mitochondrial medicine specialist"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...